Reacción a "Secondary tumours caused by CAR-T cell therapy very rare, study finds"

It is a scientifically impeccable work that puts in black and white what others have already shown: the concerns are nothing more than this and the side events do not depend in a very clear way on the CAR-T therapy itself. 

Rather than very novel, it presents well elaborated and analysed data. 

There are always limitations, but they are globally dissipated in a risk-benefit assessment.